newswise.com
Researchers at UCLA have developed a cutting-edge, non-invasive imaging technique that could revolutionize the diagnosis of clear-cell renal cell carcinoma, the most common form of kidney cancer. By offering improved accuracy in detecting malignant tumors, the method promises to reduce unnecessary surgeries and improve patient outcomes. This breakthrough, published in The Lancet Oncology, could significantly change how kidney cancer is diagnosed and treated in the future.
The new technique uses 89Zr-TLX250, a monoclonal antibody drug that targets the CA9 protein, which is highly expressed in clear-cell renal cell carcinoma. In a phase 3 clinical trial involving 332 patients, the method demonstrated high sensitivity (85.5%) and specificity (87.0%) in detecting cancerous masses, even in tumors smaller than 2 cm. This represents a significant improvement over traditional imaging methods like CT and MRI, which often struggle to distinguish between benign and malignant kidney tumors.
This development is particularly important given the aggressive nature of clear-cell renal cell carcinoma, which accounts for the majority of kidney cancer deaths. Early detection is critical, as survival rates drop significantly when the cancer is diagnosed late. By enabling earlier, more accurate diagnoses, this imaging technique has the potential to improve survival rates while also reducing unnecessary surgeries. If widely adopted, it could become a new standard in kidney cancer diagnostics and potentially aid in identifying metastatic disease, providing even more targeted treatment options for patients.